資料載入中.....
|
請使用永久網址來引用或連結此文件:
https://ir.cnu.edu.tw/handle/310902800/34450
|
| 標題: | Real-World Experience with Coformulated Ledipasvir and Sofosbuvir for HIV-Positive Patients with HCV Genotype 2 Infection: A Multicenter, Retrospective Study |
| 作者: | Liou, Bo-Huang
Sun, Hsin-Yun
Yang, Chia-Jui
Syue, Ling-Shan
Lee, Yu-Lin
Tang, Hung-Jen
Tsai, Hung-Chin
Lin, Chi-Ying
Chen, Tun-Chieh
Lee, Chun-Yuan
Huang, Sung-Hsi
Liu, Chia-Wei
Lu, Po-Liang
Lin, Shih-Ping
Wang, Ning-Chi
Cheng, Aristine
Ko, Wen-Chien
Cheng, Shu-Hsing
Hung, Chien-Ching |
| 貢獻者: | Hsinchu MacKay Mem Hosp, Dept Internal Med
Natl Taiwan Univ Hosp, Dept Internal Med
Natl Taiwan Univ, Coll Med
Natl Yang Ming Univ, Sch Med
Far Eastern Mem Hosp, Dept Internal Med
Natl Cheng Kung Univ Hosp, Dept Internal Med
Natl Cheng Kung Univ, Coll Med
Changhua Christian Hosp, Dept Internal Med
Dept Internal Med, Chi Mei Med Ctr
Chia Nan Univ Pharm & Sci, Dept Hlth & Nutr
Kaohsiung Vet Gen Hosp, Dept Internal Med
Natl Taiwan Univ Hosp, Yunlin Branch, Dept Internal Med, Huwei Township
Kaohsiung Municipal Tatung Hosp, Dept Internal Med
Kaohsiung Med Univ Hosp, Dept Internal Med, Kaohsiung, Taiwan;[Chen, Tun-Chieh;Lee, Chun-Yuan;Lu, Po-Liang
Kaohsiung Med Univ, Coll Med
Natl Taiwan Univ Hosp, Dept Internal Med, Hsinchu Branch
Natl Taiwan Univ, Dept Trop Med & Parasitol, Coll Med
Taichung Vet Gen Hosp, Dept Internal Med
Triserv Gen Hosp, Dept Internal Med
Natl Def Med Ctr
Taoyuan Gen Hosp, Dept Infect Dis, Minist Hlth & Welf
Taipei Med Univ, Sch Publ Hlth |
| 關鍵字: | Antiretroviral therapy
Direct-acting antivirals
End-of-treatment response
Estimated glomerular filtration rate
Ledipasvir
Sofosbuvir
Sustained virologic response |
| 日期: | 2021 |
| 上傳時間: | 2023-11-11 11:53:27 (UTC+8) |
| 出版者: | SPRINGER LONDON LTD |
| 摘要: | Introduction While coformulated ledipasvir (90 mg)/sofosbuvir (400 mg) (LDV/SOF) is approved for the treatment of hepatitis C virus (HCV) genotype 2 (GT2) infection in Taiwan, Japan, and New Zealand, data regarding its use for HIV (Human Immunodeficiency Virus)-positive patients infected with HCV GT2 are sparse. We aimed to assess the effectiveness and tolerability of LDV/SOF for HIV-positive patients with HCV GT2 coinfection. Methods From January 2019 to July 2020, consecutive HIV-positive Taiwanese patients infected with HCV GT2 who received LDV/SOF were retrospectively included for analysis. The effectiveness was determined by sustained virologic response 12 weeks off-therapy (SVR12). Results Of the 114 patients (mean age, 38.6 years) initiating LDV/SOF during the study period, 0.9% had liver cirrhosis and 4.4% were HCV treatment-experienced. All patients had estimated glomerular filtration rate (eGFR) > 30 ml/min/1.73 m(2) and were receiving antiretroviral therapy with 98.2% having CD4 counts >= 200 cells/mm(3) and 93.9% plasma HIV RNA load < 50 copies/ml. Antiretrovirals prescribed included tenofovir alafenamide/emtricitabine in 42.1%, tenofovir disoproxil fumarate (TDF)/emtricitabine 18.4%, other nucleoside reverse transcriptase inhibitors (NRTIs) 39.5%, non-NRTIs 12.3%, protease inhibitors 13.2%, and integrase inhibitors 74.6%. All patients had undetectable plasma HCV RNA load at the end of treatment, and 96.5% achieved SVR12 in intention-to-treat analysis. The on-treatment eGFR decline was more pronounced in those receiving TDF-containing antiretroviral therapy (mean change, - 8.33 ml/min/1.73 m(2)), which was reversible after discontinuation of LDV/SOF. None of the patients interrupted LDV/SOF during the 12-week treatment course. Conclusion Similar to the response observed among HIV-negative patients, LDV/SOF is effective for HIV-positive patients coinfected with HCV GT2. |
| 關聯: | INFECT DIS THER, v.10, n.2, pp.827-838 |
| 顯示於類別: | [保健營養系(所) ] 期刊論文
|
文件中的檔案:
| 檔案 |
描述 |
大小 | 格式 | 瀏覽次數 |
|---|
| index.html | | 0Kb | HTML | 220 | 檢視/開啟 | | s40121-021-00424-8.pdf | | 440Kb | Adobe PDF | 72 | 檢視/開啟 |
|
在CNU IR中所有的資料項目都受到原著作權保護.
|
